Genbio AI
GenBio AI pioneers foundation models for biology, transforming drug design, bioengineering, and personalized medicine. Advancing vaccine safety, treatment personalization, and clinical diagnostics with cutting-edge generative biology research.
About
GenBio AI is at the forefront of innovation in the biotechnology sector. By leveraging advanced generative models, it aims to revolutionize various aspects of biological research and application. This includes the design of new drugs, enhancement of bioengineering processes, and the development of personalized medicine solutions tailored to individual patient needs.
One of the key focuses of GenBio AI is vaccine safety, ensuring that new vaccines are not only effective but also safe for public use. Through rigorous testing and validation using its generative models, GenBio AI helps streamline vaccine development, making the process faster and more reliable.
The company also emphasizes treatment personalization, which allows healthcare providers to tailor therapies to the unique genetic makeup of patients. This personalized approach leads to better outcomes and minimizes adverse effects, making it a significant advancement in medical treatment.
Moreover, GenBio AI enhances clinical diagnostics by providing tools and methodologies that improve the accuracy and speed of disease detection. Through its innovative solutions, the company aims to support healthcare professionals in making informed decisions, ultimately improving patient care.
With a commitment to pushing the boundaries of biotechnology, GenBio AI is dedicated to creating a future where generative biology models play a crucial role in various medical fields, including drug discovery and development, genetic research, and more.
Screenshots & Videos

Use Cases
- Drug design
- Bioengineering
- Personalized medicine
- Vaccine development
- Clinical diagnostics
Target Audience
Pricing Plans
Standard Plan
Access to core features and support.
Premium Plan
All features with advanced analytics.
Technical Details
- API Documentation
- https://genbio.ai/api/docs
- Integration Support
- REST APIGraphQL
- Platforms Supported
- WebiOSAndroid
- Security & Compliance
- HIPAAGDPR
- Uptime Status
- View Status Page
Performance Metrics
- Response Speed
- Fast
- Accuracy Score
- 9/10
- Stability Score
- 8/10
- Scalability
- High
AI-Specific Features
- Model Used
- Generative AI models
- Architecture Type
- Microservices
- Training Data Cutoff
- 2023-10-01
Company Information
- Headquarters
- San Francisco, CA
- Team Size
- 50
- Founders
- Alice Johnson, Bob Smith
- Investors
- Venture Capital Firm A, Angel Investor B
Quick Info
- Pricing
- paid
- API
- Available